Raul Franco Gutierrez

Dr. Raul Franco Gutierrez

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2021 in European Heart Journal
Verified
Journal Article
Open access
PDF file
LLLuis R Lopes
Luis R Lopes
SGSoledad Garcia-Hernández
Soledad Garcia-Hernández
MLMassimiliano Lorenzini
Massimiliano Lorenzini
MFMarta Futema
Marta Futema
Olga S. ChumakovaOlga S. Chumakova
Olga S. Chumakova
Perry ElliottPerry Elliott
Perry Elliott
The aim of this study was to determine the frequency of heterozygous truncating ALPK3 variants (ALPK3tv) in patients with hypertrophic cardiomyopathy (HCM) and confirm their pathogenicity using burden testing in independent cohorts and family co-segregation studies. In a discovery cohort of 770 index patients with HCM, 12 (1.56%) were heterozygous for ALPK3tv [odds ratio(OR) 16.11, 95% confidence interval (CI) 7.94–30.02, P = 8.05e−11] compared to the Genome Aggregation Database (gnomAD) population. In a validation cohort of 2047 HCM probands, 32 (1.56%) carried heterozygous ALPK3tv (OR 16.17, 95% CI 10.31–24.87, P < 2.2e−16, compared to gnomAD). Combined logarithm of odds score in seven families with ALPK3tv was 2.99. In comparison with a cohort of genotyped patients with HCM (n = 1679) with and without pathogenic sarcomere gene variants (SP+ and SP−), ALPK3tv carriers had a higher prevalence of apical/concentric patterns of hypertrophy (60%, P < 0.001) and of a short PR interval (10%, P = 0.009). Age at diagnosis and maximum left ventricular wall thickness were similar to SP− and left ventricular systolic impairment (6%) and non-sustained ventricular tachycardia (31%) at baseline similar to SP+. After 5.3 ± 5.7 years, 4 (9%) patients with ALPK3tv died of heart failure or had cardiac transplantation (log-rank P = 0.012 vs. SP− and P = 0.425 vs. SP+). Imaging and histopathology showed extensive myocardial fibrosis and myocyte vacuolation. Heterozygous ALPK3tv are pathogenic and segregate with a characteristic HCM phenotype. Truncating variants in ALPK3 are a cause of 1–2% of autosomal dominant hypertrophic cardiomyopathy and are associated with a phenotype characterized by extensive fibrosis and a predominantly concentric or apical pattern of left ventricular hypertrophy without left ventricular outflow tract obstruction. (A) Main phenotype characteristics and outcomes. ALPK3tv, alpha-protein kinase 3-truncating variants; CK, creatine kinase; HCM, hypertrophic cardiomyopathy; ICD, implantable cardioverter–defibrillator; LVH, left ventricular hypertrophy; LVSD, left ventricular systolic dysfunction; SCD, sudden cardiac death. (B) Cardiac magnetic resonance imaging showing the prevalent phenotype of severe mid to apical hypertrophy and extensive late gadolinium enhancement in three patients. Left to right: 4-chamber view end-diastole cine image, 4-chamber view late gadolinium enhancement image, short axis late gadolinium enhancement image. (C) Kaplan–Meier analysis comparing incidence of an outcome of heart failure death and transplant between ALP3tv patients, sarcomere positive and sarcomere negative. SARC+: sarcomere positive; SARC−: sarcomere negative.

1 April 2009 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
RMRaquel Marzoa-Rivas
Raquel Marzoa-Rivas
LPLuisa Perez-Alvarez
Luisa Perez-Alvarez
MPMaria J. Paniagua-Martin
Maria J. Paniagua-Martin
EREnrique Ricoy-Martinez
Enrique Ricoy-Martinez
XFXacobe Flores-Ríos
Xacobe Flores-Ríos
MCMaria G. Crespo-Leiro
Maria G. Crespo-Leiro

1 October 2019 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
RCRamón Calviño-Santos
Ramón Calviño-Santos
RERodrigo Estévez-Loureiro
Rodrigo Estévez-Loureiro
JPJesús Peteiro-Vázquez
Jesús Peteiro-Vázquez
JSJorge Salgado-Fernández
Jorge Salgado-Fernández
ARAlejandro Rodríguez-Vilela
Alejandro Rodríguez-Vilela
JVJosé Manuel Vázquez-Rodríguez
José Manuel Vázquez-Rodríguez
Background: Recent trials suggest that complete revascularization in patients with acute ST-segment–elevation myocardial infarction and multivessel disease is associated with better outcomes than infarct-related artery (IRA)–only revascularization. There are different methods to select non-IRA lesions for revascularization procedures. We assessed the clinical outcomes of complete angiographically guided revascularization versus stress echocardiography–guided revascularization in patients with ST-segment–elevation myocardial infarction. Methods: We performed a randomized clinical trial in patients with multivessel disease who underwent a successful percutaneous coronary intervention of the IRA to test differences in prognosis (composite end point included cardiovascular mortality, nonfatal reinfarction, coronary revascularization, and readmission for heart failure after 12 months of follow-up) between complete angiographically guided revascularization (n=154) or stress echocardiography–guided revascularization (n=152) of the non-IRA lesions in an elective procedure before hospital discharge. Results: The trial was prematurely stopped after the inclusion of 77% of the planned study population. As many as 152 (99%) patients in the complete revascularization group and 44 (29%) patients in the selective revascularization group required a percutaneous coronary intervention procedure of a non-IRA lesion before discharge. The primary end point occurred in 21 (14%) patients of the stress echocardiography–guided revascularization group and 22 (14%) patients of the complete angiographically guided revascularization group (hazard ratio, 0.95; 95% CI, 0.52–1.72; P =0.85). Conclusions: In patients with ST-segment–elevation myocardial infarction and multivessel disease, stress echocardiography–guided revascularization may not be significantly different to complete angiographically guided revascularization, thereby reducing the need for elective revascularization before hospital discharge. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01179126.

1 September 2007 in Transplantation Proceedings
Verified
Journal Article
Closed access
RMR. Marzoa
R. Marzoa
MCM.G. Crespo-Leiro
M.G. Crespo-Leiro
MPM.J. Paniagua
M.J. Paniagua
IBI. Bendayán
I. Bendayán
RRR. Rios
R. Rios
ACA. Castro-Beiras
A. Castro-Beiras

1 November 2008 in Transplantation Proceedings
Verified
Journal Article
Closed access
MCM.G. Crespo-Leiro
M.G. Crespo-Leiro
MPM.J. Paniagua
M.J. Paniagua
RMR. Marzoa
R. Marzoa
ZGZ. Grille
Z. Grille
CNC. Naya
C. Naya
ACA. Castro-Beiras
A. Castro-Beiras

1 September 2007 in Transplantation Proceedings
Verified
Journal Article
Closed access
MCM.G. Crespo-Leiro
M.G. Crespo-Leiro
MPM.J. Paniagua
M.J. Paniagua
RGRaul Franco Gutierrez
Raul Franco Gutierrez
RMR. Marzoa
R. Marzoa
ZGZ. Grille
Z. Grille
ACA. Castro-Beiras
A. Castro-Beiras